References
Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586
Eichelbaum M, Spannbrucker N, Steinecke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187
Gonzales FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Mayer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 33: 442–446
Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, Dayer P (1986) Molecular mechanisms of two common polymorphisms of drug oxidation. Evidence for functional changes in cytochrome P-450 isozymes catalyzing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464
Price Evans DA (1986) In: Kalow W, Goedde HW, Agarwal DP (eds) Ethnic differences in reactions to drugs and xenobiotics. New York, Liss, 491–526 (Progress in clinical and biological research, 214)
Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618–624
Von Bahr C, Guengerich FP, Movin G, Nordin C (1985) The use of human liver banks in pharmacogenetic research. In: Dahl SG, Gram LF (eds) Clinical Pharmacology in Psychiatry. Springer, Berlin Heidelberg New York Tokyo
Baumann P, Jonzier-Perey M (1988) GC and GC-Ms procedures for simultaneous phenotyping with dextromethrophan and mephenytoin. Clin Chim Acta 171: 211–222
Kilts CD, Patrick KS, Breese GR, Mailman RB (1982) Simultaneous determination of thioridazine and its S-oxidized and N-demthylated metabolites using high-performance liquid chromatography on radially compressed silica. J Chromatogr 231: 377–391
Skoda RC, Gonzales FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450dbl (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240–5243
Author information
Authors and Affiliations
Additional information
Supported by Swiss National Science Foundation (32-8651.85/2)
Rights and permissions
About this article
Cite this article
Meyer, J.W., Woggon, B., Baumann, P. et al. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39, 613–614 (1990). https://doi.org/10.1007/BF00316110
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316110